Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Executive Summary
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
You may also be interested in...
Mallinckrodt Creating Two Companies: Generics And Innovative Specialty Drugs
The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Getting Things Moving: Opportunities In Opioid-Induced Constipation
With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.